Giuseppe Fornarini

Head of disease management team of genitourinary neoplasm

Ospedale Policlinico San Martino

Italy

Research Interests

Explore related searches

Professors in Italy

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Giuseppe Fornarini is the Head of the Disease Management Team of Genitourinary Neoplasm at IRCCS Ospedale Policlinico San Martino in Italy. His research areas focus on innovative treatments and management strategies for various genitourinary cancers, including prostate and renal cell carcinoma. His recent publications include significant contributions to the understanding of neoadjuvant therapies, radioligand therapies, and the prognostic factors in metastatic castration-resistant prostate cancer.

Articles (10)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Collaborators (3)

Giuseppe De Vincentis

Associated Professor

Sapienza University of Rome

ITALY

View details

Gianmario Sambuceti

Head

Ospedale Policlinico San Martino

ITALY

View details

Alessio Farcomeni

ITALY

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Giuseppe Fornarini

Research Interests

Explore related searches

Contact this professor

About

Articles (10)

Large Italian Multicenter Study on Prognostic Value of Baselines Variables in mCRPC Patients Treated with <sup>223</sup>RaCl<sub>2</sub>: Ten Years of Clinical Experience

Interpretation of PSMA-PET Among Urologists: A Prospective Multicentric Evaluation

A Comprehensive Approach to Neoadjuvant Treatment of Locally Advanced Rectal Cancer

Defining the Position of [177Lu]Lu-PSMA Radioligand Therapy in the Treatment Landscape of Metastatic Castration-Resistant Prostate Cancer: A Meta-analysis of Clinical Trials

Association of myeloid-derived suppressor cell (MDSC) dynamics with clinical response to nivolumab in metastatic clear cell renal carcinoma patients (mRCC): Results from the I-RENE Meet-URO 8 study

Commentary: Sodium levels and immunotherapy efficacy in mRCC patients with bone metastases: sub analysis of the Meet-Uro 15 study

First-line immune-based combinations or sunitinib in favorable-risk metastatic renal cell carcinoma: a real-world retrospective comparison from the ARON-1 study

Impact of initial local therapy (LT) in the combination treatment era for metastatic renal cell carcinoma (mRCC): Subgroup analysis from ProPaxi study

Initial management approach for localized/locally advanced disease is critical to guide metastatic castration-resistant prostate cancer care

PERSIAN trial: Early results from a randomized phase II trial testing apalutamide and stereotactic body radiation therapy for low-burden, metastatic, hormone-sensitive prostate cancer

Collaborators (3)

Giuseppe De Vincentis

Gianmario Sambuceti

Alessio Farcomeni

Make your next move.